Table 2.
Differences in the secondary outcome measure between the three trial arms
| SBNT (n = 26) | PGS (n = 27) | TAU (n = 30) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Item | Baseline | 3 months | 12 months | Baseline | 3 months | 12 months | Baseline | 3 months | 12 months |
| Days abstinent from heroin, median (IQR) | 15 (8,24) | 18 (2,22) | 17 (11,23) | 18 (8,24) | 18 (8,20) | 18 (8,27) | 20 (12,26) | 23 (14,26) | 25 (14,27) |
| LDQ total, median (IQR) | 14 (8,17) | 9 (5,16) | 10 (6.6,16) | 11 (5,15) | 6 (5,12) | 7 (4,10) | 7 (2,13) | 6 (3,12) | 5 (2,13) |
| CORE | |||||||||
| Wellbeing, median (IQR) | 2 (2,3) | 2 (0.8,2.5) | 2 (1.3,2.9) | 2 (1,2) | 1.6 (0.8,2.1) | 1.5 (0.8,2) | 2 (1,2) | 1.3 (0.8,2) | 1.5 (0.8,2.3) |
| Symptoms, median (IQR) | 2 (2,3) | 2.1 (0.9,2.9) | 2.4 (1.1,2.6) | 2 (1,2) | 1.3 (1,2.3) | 1.5 (0.8,2) | 2 (1,3) | 1.3 (1,2.3) | 1.6 (0.8,2.3) |
| Functioning, median (IQR) | 2 (2,3) | 1.8 (1.2,2.6) | 2.2 (1,2.7) | 2 (1,2) | 1.5 (1.1,2) | 1.6 (0.8,2) | 2 (1,2) | 1.5 (1.1,2.1) | 1.2 (0.8,1.9) |
| SSQ total, median (IQR) | 23 (19,26) | 24 (22,28) | 24 (19.5,27) | 22 (18,25) | 23 (19,24) | 22 (20,26) | 23 (20,27) | 24 (20,28) | 24 (22,27) |
| CEST | |||||||||
| Counselling rapport, median (IQR) | 40 (38,43) | 41 (38,43) | 39 (35,46) | 39 (36,42) | 39 (38,42) | 40 (39,42) | 40 (39,43) | 40 (39,44) | 41 (40,48) |
| Peer support, median (IQR) | 32 (28,40) | 30 (26,38) | 30 (25,37) | 30 (28,34) | 30 (28,32) | 30 (26,34) | 32 (28,38) | 32 (26,36) | 36 (28,38) |
| Treatment participation, median (IQR) | 38 (33,39) | 38 (36,39) | 38 (31,42) | 37 (35,38) | 37 (35,38) | 38 (35,40) | 38 (34,41) | 39 (37,42) | 41 (40,47) |
| Treatment satisfaction, median (IQR) | 39 (35,41) | 40 (36,43) | 40 (35,40) | 39 (37,41) | 39 (37,41) | 40 (36,42) | 40 (39,43) | 40 (39,44) | 41 (40,47) |
| ISEL | |||||||||
| Appraisal, median (IQR) | 16 (15,19) | 17 (15,18) | 18 (14,21) | 16 (14,18) | 18 (16,20) | 18 (16,20) | 16 (15,18) | 18 (17,20) | 18 (16,20) |
| Belonging, median (IQR) | 17 (14,19) | 16 (14,18) | 17 (14,19.5) | 15 (13,17) | 17 (15,19.5) | 16 (14.5,19.5) | 17 (15,18) | 17 (16,20) | 18 (15,21.5) |
| Self-esteem, median (IQR) | 14 (12,17) | 14 (13,15) | 13.5 (12,16.5) | 14 (12,16) | 15 (14,17) | 15 (14,18) | 16 (13,18) | 15 (14,18) | 15 (14,20) |
| Tangible, median (IQR) | 17 (13,19) | 16 (14,19) | 16 (14,19.5) | 15 (14,19) | 16 (15,19) | 18 (14.5,19.5) | 16 (14,18) | 16 (14,17) | 17.5 (15.5,21) |
| IPDA | |||||||||
| Index 1-network size (IQR) | −0.42 (−0.66,0.24) | 0.07 (−0.83,0.83) | −0.29 (−0.74,1.01) | − 0.18 (− 0.66,0.64) | −0.14 (− 0.83,0.65) | 0.12 (− 0.74,0.49) | 0.24 (− 0.18,1.0) | 0.07 (− 0.83,1.18) | 0.12 (− 0.29,0.84) |
| Index 2–daily network size (IQR) | − 0.50 (−1.06,0.06) | − 0.10 (− 0.58,0.37) | −0.49 (− 0.76,0.06) | −0.06 (− 0.50,1.18) | −0.10 (− 0.58,0.37) | −0.49 (− 0.49,0.61) | −0.22 (− 0.50,0.06) | −0.50 (− 0.50,0.62) | 0.06 (− 0.49,0.61) |
| Index 3-importance (IQR) | −0.14 (− 0.65,0.62) | 0.17 (− 0.33,0.75) | −0.12 (− 0.58,0.67) | −0.02 (− 1.08,1.25) | −0.01 (− 0.89,0.94) | −0.12 (− 0.62,0.38) | −0.02 (− 0.86,1.25) | −0.01 (− 0.43,0.75) | 0.38 (− 0.12,1.14) |
| Component 1: substance involvement (IQR) | −0.40 (− 0.93,0.05) | −0.35 (− 0.83,0.62) | −0.28 (− 0.79,1.14) | −0.06 (− 0.44,0.67) | −0.24 (− 0.51,0.34) | −0.37 (− 0.84,0.16) | −0.24 (− 0.75,0.85) | −0.49 (− 0.66,0.47) | −0.07 (− 0.58,0.57) |
| Component 2: general/treatment support (IQR) | 0.14 (− 0.56,0.66) | −0.04 (− 0.48,0.57) | 0.24 (− 0.58,0.66) | −0.49 (− 1.03, 0.30) | −0.10 (− 0.50,0.74) | −0.14 (− 0.83,0.43) | 0.48 (− 0.35,1.02) | 0.09 (− 0.17,0.77) | 0.34 (− 0.30,0.82) |
| Component 3-support for substance use (IQR) | 0.16 (− 0.86,0.89) | 0.25 (− 0.75,0.82) | 0.48 (− 0.72,1.37) | 0.34 (− 0.86,0.89) | 0.08 (−0.75,0.68) | − 0.51 (− 0.94,0.90) | 0.02 (− 0.86,0.72) | 0.07 (− 1.02,0.57) | −0.51 (− 0.94,0.68) |
| RCQ-TV, median (IQR) | 4.5 (4,7) | 5 (4,6) | 4 (4,7) | 4 (3,5) | 4 (3,5) | 4 (4,6) | 4.5 (4,6) | 4 (4,6) | 5 (4,7) |